This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Pneumonia

  1. This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention. Sources of information for these trials are clinicaltrials.gov; who.int/ctrp; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries. Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. (This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.)
    Published: October 2019
    Type: Resource Page
  2. We make vaccines affordable for low-resource countries—and so do our partners
    Published: October 2019
    Type: Article
  3. This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on worldwide. (This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.)
    Published: August 2019
    Type: Resource Page
  4. This brief, developed by the Advancing Maternal Immunization (AMI) collaboration, describes the activities required in the near- and mid-to long-term to generate key evidence and achieve the necessary conditions for advancing respiratory syncytial virus (RSV) maternal immunization in low- and middle-income countries. It is a companion to AMI's Advancing RSV Maternal Immunization: A Gap Analysis Report, which describes the evidence, information, and policy needs of global and country decision-makers, public health program planners, and implementers who might be involved in decision-making and introducing maternal RSV vaccines.AMI is a collaboration of cross-sectoral experts convened by PATH and WHO with the purpose of advancing RSV maternal immunization.Related links:A Roadmap for Advancing RSV Maternal ImmunizationAdvancing Maternal ImmunizationAdvancing RSV Maternal Immunization: A gap analysis brief
    Published: May 2019
    Type: Resource Page
  5. PATH is on the front lines of an effort to defeat meningitis by 2030.
    Published: April 2019
    Type: Article
  6. The United States has a long history of leadership in global immunization. This educational fact sheet created by PATH and several advocacy partners highlights US government efforts in global immunization, including support for Gavi, the Vaccine Alliance; UNICEF; and the World Health Organization, as well as immunization activities carried out by the US Agency for International Development, US Department of Defense, and various agencies within the Department of Health and Human Services.
    Published: March 2019
    Type: Resource Page
  7. Drug resistance is one of the biggest threats to global health today. Vaccines can help.
    Published: January 2019
    Type: Article
  8. Oxygen therapy paired with pulse oximetry is being used to treat hypoxemia and save lives in Uganda. This brief outlines political recommendations for scaling up its use.
    Published: December 2018
    Type: Resource Page
  9. Strong national programs and civil society partnerships at all levels contribute to Kenya's progress against pneumonia and diarrhea.
    Published: November 2018
    Type: Article
  10. New vaccines on the horizon, if successful, could help resource-strapped countries make valuable headway against the world’s #1 child killer—pneumonia.
    Published: November 2018
    Type: Article
Load more